The Company's Board of Director's resolution on the
execution of syndicated loan
Date of events
2022/08/12
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/08/12
2.Company name: Bora Pharmaceuticals Co., Ltd.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:To stregthen the Company's working capital to acquire
TWI Pharmaceuticals, Inc.'s all stock, the Company's Board of Director
approve to appoint China Trust Bank as the in charge for the syndicated
loan, total amounted to NTD 4 billion to 5 billion for a period of 5 year.
6.Countermeasures:NA
7.Any other matters that need to be specified:For the application
and contract signing of the syndicated loan, The Company's Board
of Directors authorize the chairman to take the necessary action.
Attachments
Original Link
Original Document
Permalink
Disclaimer
Bora Pharmaceuticals Co. Ltd. published this content on 12 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 12 August 2022 12:14:13 UTC.
Bora Pharmaceuticals Co Ltd is a Taiwan-based company principally engaged in the agency and sales of western medicines, as well as the research, development, manufacture and sales of new drugs and health products. The Company's main products are categorized into prescription drugs and health care products, including central nervous drugs, cardiovascular drugs, antibiotics, antiviral agents, ophthalmic drugs, gastrointestinal drugs, foam ingots and health care products. In addition, the Company has biopharmaceutical technologies related to the development of cell lines for the production of protein drugs, the development and analysis of upstream and downstream processes, as well as the establishment of quality control and testing specifications and the creation of cell banks.
BORA PHARMACEUTICALS CO., LTD. 
